Cumberland Pharmaceuticals Share Price (NASDAQ: CPIX)

$3.51

▲

0.04

(1.15%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Cumberland Pharmaceuticals Stock chart to analyse performance

Cumberland Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.41
Today's High:$3.51
$3.51
2.85%
Downside
Day's Volatility :2.85%
Upside
0.0%
52 Weeks Low:$1.04
52 Weeks High:$7.25
$3.51
70.37%
Downside
52 Weeks Volatility :85.66%
Upside
51.59%

Cumberland Pharmaceuticals Stock Returns

Period	Cumberland Pharmaceuticals Inc	Index (Russel 2000)
3 Months	-38.88%	0.0%
6 Months	-32.1%	0.0%
1 Year	158.52%	0.0%
3 Years	53.07%	-4.7%

Cumberland Pharmaceuticals Inc Key Stats

Check Cumberland Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.47
Open	$3.43
Today's High	$3.51
Today's Low	$3.41
Market Capitalization	$51.9M
Today's Volume	$20.7K
52 Week High	$7.25
52 Week Low	$1.04
Revenue TTM	$42.1M
EBITDA	$1.7M
Earnings Per Share (EPS)	$-0.22
Profit Margin	-6.97%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-10.89%

Stock Returns calculator for Cumberland Pharmaceuticals Stock including INR - Dollar returns

The Cumberland Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cumberland Pharmaceuticals investment value today

Current value as on today

₹2,65,284

Returns

₹1,65,284

(+165.28%)

Returns from Cumberland Pharmaceuticals Stock

₹1,60,000 (+160%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Cumberland Pharmaceuticals Stock

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Cumberland Pharmaceuticals Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cumberland Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
Millennium Management LLC
5.41%
Ikarian Capital, LLC
4.95%
Renaissance Technologies Corp
3.36%
Vanguard Group Inc
2.75%
Dimensional Fund Advisors, Inc.
1.69%
J. Goldman & Co LP
1.61%

Analyst Recommendation on Cumberland Pharmaceuticals Stock

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for Cumberland Pharmaceuticals(by analysts ranked 0 to 5 stars)

Cumberland Pharmaceuticals Share Price Target

What analysts predicted

Upside of 142.17%

Target:

$8.50

Current:

$3.51

Cumberland Pharmaceuticals share price target is $8.50, a slight Upside of 142.17% compared to current price of $3.51 as per analysts' prediction.

Cumberland Pharmaceuticals Stock Insights

Price Movement
In the last 7 days, CPIX stock has moved up by 6.1%
Decreasing Revenue
Revenue is down for the last 2 quarters, 11.71M → 10.83M (in $), with an average decrease of 7.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 1.25M → -740.74K (in $), with an average decrease of 158.9% per quarter

Cumberland Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$34.4M	↓ 15.59%
Net Income	$-9.2M	↑ 32.29%
Net Profit Margin	-26.79%	↓ 9.7%

	FY20	Y/Y Change
Revenue	$37.4M	↑ 8.88%
Net Income	$-6.6M	↓ 28.07%
Net Profit Margin	-17.7%	↑ 9.09%

	FY21	Y/Y Change
Revenue	$36.0M	↓ 3.89%
Net Income	$-5.6M	↓ 15.53%
Net Profit Margin	-15.55%	↑ 2.15%

	FY22	Y/Y Change
Revenue	$42.0M	↑ 16.75%
Net Income	$-5.7M	↑ 0.95%
Net Profit Margin	-13.45%	↑ 2.1%

	FY23	Y/Y Change
Revenue	$39.6M	↓ 5.85%
Net Income	$-6.3M	↑ 11.14%
Net Profit Margin	-15.88%	↓ 2.43%

	FY24	Y/Y Change
Revenue	$37.9M	↓ 4.26%
Net Income	$-6.5M	↑ 3.19%
Net Profit Margin	-17.11%	↓ 1.23%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$8.5M	↓ 9.15%
Net Income	$-1.9M	↓ 69.06%
Net Profit Margin	-22.9%	↑ 44.36%

	Q2 FY24	Q/Q Change
Revenue	$9.8M	↑ 15.9%
Net Income	$-1.1M	↓ 44.22%
Net Profit Margin	-11.02%	↑ 11.88%

	Q3 FY24	Q/Q Change
Revenue	$9.1M	↓ 7.75%
Net Income	$-1.5M	↑ 42.23%
Net Profit Margin	-16.99%	↓ 5.97%

	Q4 FY24	Q/Q Change
Revenue	$10.4M	↑ 14.86%
Net Income	$-1.9M	↑ 23.3%
Net Profit Margin	-18.24%	↓ 1.25%

	Q1 FY25	Q/Q Change
Revenue	$11.7M	↑ 12.24%
Net Income	$1.3M	↓ 166.03%
Net Profit Margin	10.73%	↑ 28.97%

	Q2 FY25	Q/Q Change
Revenue	$10.8M	↓ 7.48%
Net Income	$-740.7K	↓ 158.93%
Net Profit Margin	-6.84%	↓ 17.57%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$27.0M	↓ 19.17%

	FY20	Y/Y Change
Profit	$28.8M	↑ 6.75%

	FY21	Y/Y Change
Profit	$27.2M	↓ 5.61%

	FY22	Y/Y Change
Profit	$32.9M	↑ 21.04%

	FY23	Y/Y Change
Profit	$33.5M	↑ 1.8%

	FY24	Y/Y Change
Profit	$31.3M	↓ 6.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$5.8M	↓ 12.92%

	Q2 FY24	Q/Q Change
Profit	$7.0M	↑ 21.26%

	Q3 FY24	Q/Q Change
Profit	$7.8M	↑ 10.92%

	Q4 FY24	Q/Q Change
Profit	$8.5M	↑ 8.97%

	Q1 FY25	Q/Q Change
Profit	$10.3M	↑ 21.61%

	Q2 FY25	Q/Q Change
Profit	$8.8M	↓ 14.21%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$3.1M	↓ 1.81%
Investing Cash Flow	$2.3M	↓ 108.29%
Financing Cash Flow	$-5.1M	↓ 171.17%

	FY20	Y/Y Change
Operating Cash Flow	$5.4M	↑ 77.17%
Investing Cash Flow	$-1.8M	↓ 176.5%
Financing Cash Flow	$-7.1M	↑ 40.07%

	FY21	Y/Y Change
Operating Cash Flow	$6.3M	↑ 17.13%
Investing Cash Flow	$-501.9K	↓ 71.45%
Financing Cash Flow	$-3.6M	↓ 50.06%

	FY22	Y/Y Change
Operating Cash Flow	$8.5M	↑ 33.28%
Investing Cash Flow	$-13.7M	↑ 2624.58%
Financing Cash Flow	$-2.1M	↓ 41.98%

	FY23	Y/Y Change
Operating Cash Flow	$6.1M	↓ 27.91%
Investing Cash Flow	$-105.7K	↓ 99.23%
Financing Cash Flow	$-7.4M	↑ 260.1%

	FY24	Y/Y Change
Operating Cash Flow	$-612.2K	↓ 110.05%
Investing Cash Flow	$57.8K	↓ 154.73%
Financing Cash Flow	$196.9K	↓ 102.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.1M	↓ 305.42%
Investing Cash Flow	$-58.2K	↓ 122.32%
Financing Cash Flow	$2.4M	↓ 262.85%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-855.7K	↓ 59.95%
Investing Cash Flow	$-46.8K	↓ 19.56%
Financing Cash Flow	$-309.6K	↓ 112.78%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$475.5K	↓ 155.57%
Investing Cash Flow	$189.6K	↓ 505.18%
Financing Cash Flow	$-536.8K	↑ 73.41%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$1.9M	↑ 300.55%
Investing Cash Flow	$-26.8K	↓ 114.14%
Financing Cash Flow	$-1.4M	↑ 156.76%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$3.9M	↑ 104.69%
Investing Cash Flow	$-1.2M	↑ 4481.25%
Financing Cash Flow	$-5.5M	↑ 300.91%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$843.8K	↓ 78.36%
Investing Cash Flow	$285.9K	↓ 123.28%
Financing Cash Flow	$-150.8K	↓ 97.27%

Cumberland Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Cumberland Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Cumberland Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cumberland Pharmaceuticals Inc	1.16%	-32.1%	158.52%	53.07%	6.73%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cumberland Pharmaceuticals Inc	NA	NA	0.0	0.0	-0.11	-0.03	NA	1.87
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cumberland Pharmaceuticals Inc	Sell	$51.9M	6.73%	NA	-6.97%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Organization	Cumberland Pharmaceuticals
Employees	91
CEO	Mr. A. J. Kazimi MBA
Industry	Health Technology

Key Management of Cumberland Pharmaceuticals Inc

Name	Title
Mr. A. J. Kazimi MBA	Founder, Chairman, President & CEO
Mr. John Michael Hamm C.M.A.	VP & CFO
Mr. James Lowrance Herman	VP of Trade & Distribution and Chief Compliance Officer
Mr. ChristopherT. Bitterman	Vice President of Sales & Marketing
Mr. Todd M. Anthony	Vice President of Organizational Development
Ms. Jean W. Marstiller	Senior VP of Administrative Services & Corporate Secretary
Mr. Adam S. Mostafa	Managing Director of Banking & Investor Relations

Important FAQs about investing in CPIX Stock from India :

What is Cumberland Pharmaceuticals share price today?

Cumberland Pharmaceuticals share price today is $3.51 as on August 30, 2025 at 1:29 am IST at the close of the market. Cumberland Pharmaceuticals share today touched a day high of $3.51 and a low of $3.41.

What is the 52 week high and 52 week low for Cumberland Pharmaceuticals share?

Cumberland Pharmaceuticals share touched a 52 week high of $7.25 and a 52 week low of $1.04. Cumberland Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.51, lower by 51.59% versus the 52 week high.

How to invest in Cumberland Pharmaceuticals Stock (CPIX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cumberland Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cumberland Pharmaceuticals Shares that will get you 0.4274 shares as per Cumberland Pharmaceuticals share price of $3.51 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cumberland Pharmaceuticals Stock (CPIX) from India?

Indian investors can start investing in Cumberland Pharmaceuticals (CPIX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Cumberland Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Cumberland Pharmaceuticals share’s latest price of $3.51 as on August 30, 2025 at 1:29 am IST, you will get 2.8490 shares of Cumberland Pharmaceuticals. Learn more about fractional shares .

What are the returns that Cumberland Pharmaceuticals has given to Indian investors in the last 5 years?

Cumberland Pharmaceuticals stock has given 6.73% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?